Development of the ambroxol gels for enhanced transdermal delivery

Drug Development and Industrial Pharmacy

Volumn 34, Issue 3, 2008, Pages 330-335

  Cho, Cheong Weon ^a   Choi, Jun Shik ^b   Shin, Sang Chul ^c  

^a Chungnam National University   (South Korea)

^b Chosun University   (South Korea)

^c Chonnam National University   (South Korea)

Author keywords

Activation energy of permeation; Ambroxol; Drug delivery; Gels; Permeation enhancer

Indexed keywords

ACYLGLYCEROL; AMBROXOL; CAPRYLOCAPROYL MACROGOL 8 GLYCERIDE; DIETHYLENE GLYCOL; ETHYLENE GLYCOL; FATTY ACID; HYDROXYPROPYLMETHYLCELLULOSE; NONIONIC SURFACTANT; OCTANOIC ACID; OLEIC ACID; OLEOYL MACROGOL 6 GLYCERIDE; POLIDOCANOL; POLOXAMER; POLYOXYETHYLENE OLEYL ETHER; POLYOXYETHYLENE STEARYL ETHER; PROPYLENE GLYCOL; PROPYLENE GLYCOL LAURATE; PROPYLENE GLYCOL MONO CAPRYLATE; PROPYLENE GLYCOL MONO LAURATE; TETRAETHYLENE GLYCOL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CALCULATION; DRUG DELIVERY SYSTEM; DRUG FORMULARY; DRUG PENETRATION; DRUG RELEASE; ENERGY; GEL; MALE; MOUSE; NONHUMAN; SKIN PENETRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, CUTANEOUS; AMBROXOL; ANIMALS; DRUG CARRIERS; ETHYLENE GLYCOLS; EXCIPIENTS; EXPECTORANTS; FATTY ACIDS; GELS; GLYCERIDES; MALE; METHYLCELLULOSE; POLOXAMER; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SKIN ABSORPTION; TEMPERATURE;

EID: 41149126016     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701662644     Document Type: Article

References (18)

1. Aungst, B. J., Rogers, N. J., & Shegter, E. (1986). Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int. J. Pharm., 33, 225-234.
2. Chien, Y. W., & Lau E. P. K. (1976). Controlled drug release from polymeric delivery devices IV: In vitro-in vivo correlation of subcutaneous release of norgestomet from hydrophilic implants. J. Pharm. Sci., 65, 488-492.
3. Coutel-Egros, A., Maitani, Y., Veillard, M., Machida, Y., & Nagai, T. (1992). Combined effects of pH cosolvent and penetration enhancers on the in vitro buccal absorption of propanolol through excised hamster cheek pouch. Int. J. Pharm., 84, 117, 128.
4. Dariusz, N. D., Antczak, A., & Król, M. (1994). Antioxidant properties of ambroxol. Free Radical Biology and Medicine, 16, 517-522.
5. Diaz, J. P., Manresa, P. F., Benasco, C., Guardioia, J., Munoz, L., & Clariana, A. (1984). Response to surfactant activator (ambroxol) in alveolar proteinosis. Lancet, 1 (8384), 1023.
6. Durrhein, H., Flynn, G. L., Higuchi, W. I., & Behl, C. R. (1980). Permeation of hairless mouse skin I: experimental methods and comparison with human epidermis permeation by alkanols. J. Pharm. Sci., 69, 781-786.
7. Ericsson, C. H., Juhasz, J., Johnson, E., & Mossberg, B. (1987). Ambroxol and simple chronic bronchitis: Effects on subjective symptoms and ventillatory function. Respiration, 51(Suppl 1), 33-36.
8. Guyatt G. H., Townsend, M., Kazim, F., & Newhouse, M. T. (1987). A controlled trial of ambroxol in chronic bronchitis. Chest, 92, 618-620.
9. Ishida, M., Machida, Y., Nambu, N., & Nakai, T. (1981). New mucosal dosage form of insulin. Chem. Pharm. Bull., 209, 810-816.
10. Kartz, M., & Polsen, B. (1971). Absorption of drugs through the skin. In Brodie, B. B., Gillette, J. R. (Eds.), Handbook of Experimental Pharmacology (pp. 103-174). New York: Springer.
11. Miyazaki, S., Takeuchi, S., Yokouchi, C., & Takada, M. (1984). Pluronic F-127 gels as a vehicle for topical administration of anticancer agents. Chem. Pharm. Bull., 32, 4205-4208.
12. Olivieri, D., Zavattini, G., Tomasini, G., Daniotti, S., Bonsignore G., Ferrara, G., Carnimeo, N., Vhianese, R., Catena E., & Marcatili, S. (1987). Ambroxol for the prevention of chronic bronchitis exacerbations: Long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: A double-blind study versus placebo. Respiration, 51, 42-51.
13. Ratjen, F., Wonne, R., Posselt, H. G., Stover, B., Hofmann, D., & Bender, S. W. (1985). A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur. J. Pediatr., 144, 374-378.
14. Severina, I. S., Bussygina, O. G., Pyatakova, N. V., Khropov Y. V., & Krasnoperov, R. A. (2000). Ambroxol as an inhibitor of nitric oxide-dependent activation of soluble guanylate cyclase. Eur. J. Pharmacology, 407, 61-64.
15. Shin, S. C., & Kim, J. Y. (2000). Enhanced permeation of triamcinolone acetonide through the buccal mucosa. Eur. J. Pharm. Biopharm., 50, 217-220.
16. Shin, S. C., Kim, J., Yoon, M. K., Oh, I. J., & Choi, J. S. (2002). Transdermal delivery of triprolidine using TPX polymer membrane. Int. J. Pharm., 235, 141-147.
17. Vanlommel, N. S., Verbeken, E. K., Lauweryns, J. K., & Demedts, M. (1992). Lung injury induced by paraquat, hyperoxia and cobalt chloride: Effects of ambroxol. Pulm. Pharmacol., 5, 53-60.
18. Vergin, H., Bishop-Freundling, G. B., Micka, M., Nitsche, V., Strobel, K., & Matzkies, F. (1985). Untersuchungen zur pharmakokinetik und bioaquivalenz unterschiedlicher darreichungsformen von ambroxol. Arzneim-Forsch./Drug Res., 35, 1591-1595.